AstraZeneca's Imfinzi misses main goal of advanced lung cancer study

FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid - Copyright BRENDAN MCDERMID(Reuters)

By Reuters

Published on 21/08/2019 - 08:34•Updated 20/04/2024 - 05:08

Comments

(Reuters) - London-listed drugmaker AstraZeneca Plc <AZN.L> said on Wednesday its immunotherapy treatment Imfinzi did not meet the main goal of a late-stage study for advanced non-small cell lung cancer.

The treatment was not successful in extending the lives of patients whose cancer had spread to other parts of the body. The primary group in the study also had high levels of mutations in their DNA, the company said.

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun Koyyur)

Comments

You might also like